Damora Therapeutics (DMRA) Enterprise Value (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Enterprise Value came in at -$202.4 million in Q1 2026, down 3280.03% YoY from $6.4 million in Q1 2025, and up 21.44% on a QoQ basis from -$257.6 million in Q4 2025.
Damora Therapeutics (DMRA) Enterprise Value (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Enterprise Value data on file, last reported at -$202.4 million in Q1 2026.
- Quarterly Enterprise Value fell 3280.03% year-over-year to -$202.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.4 million (down 3280.03% YoY) and the FY2025 annual result came in at -$257.6 million, down 1717.45% from the prior year.
- Enterprise Value grew to -$202.4 million in Q1 2026, from -$257.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$6.0 million in Q1 2025 to a low of -$257.6 million in Q4 2025.
- A 5-year average of -$67.2 million and a median of -$52.1 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value jumped 77.96% — and 2026, when it tumbled 3280.03%.
- Tracing DMRA's Enterprise Value over 5 years: stood at -$60.2 million in 2022, then surged by 38.59% to -$37.0 million in 2023, then jumped by 61.67% to -$14.2 million in 2024, then sank by 1717.45% to -$257.6 million in 2025, then climbed by 21.44% to -$202.4 million in 2026.
- The last three Enterprise Value figures came in at -$202.4 million (Q1 2026), -$257.6 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -540.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -540.52 Mn |
| Mar 31, 2026 | -202.40 Mn |
| Dec 31, 2025 | -257.62 Mn |
| Sep 30, 2025 | -7.61 Mn |
| Jun 30, 2025 | -10.21 Mn |
| Mar 31, 2025 | -5.99 Mn |
| Dec 31, 2024 | -14.18 Mn |
| Sep 30, 2024 | -19.70 Mn |
| Jun 30, 2024 | -12.73 Mn |
| Mar 31, 2024 | -27.17 Mn |
| Dec 31, 2023 | -36.98 Mn |
| Sep 30, 2023 | -61.05 Mn |
| Jun 30, 2023 | -52.12 Mn |
| Mar 31, 2023 | -53.25 Mn |
| Dec 31, 2022 | -60.22 Mn |
| Sep 30, 2022 | -101.49 Mn |
| Jun 30, 2022 | -126.89 Mn |
| Mar 31, 2022 | -93.60 Mn |
| Dec 31, 2021 | -100.19 Mn |
| Sep 30, 2021 | -102.14 Mn |